Literature DB >> 21764616

Identification of mutations causing hereditary tyrosinemia type I in patients of Middle Eastern origin.

Faiqa Imtiaz1, Mohamed S Rashed, Bashayer Al-Mubarak, Rabab Allam, Hanaa El-Karaksy, Zuhair Al-Hassnan, Mohammed Al-Owain, Hamad Al-Zaidan, Zuhair Rahbeeni, Alya Qari, Brian F Meyer, Moeen Al-Sayed.   

Abstract

Hereditary Tyrosinemia Type 1 (HT1) is an autosomal recessive disorder resulting from a deficiency of fumarylacetoacetase caused by mutations in the fumarylacetoacetate hydrolase (FAH) gene. We detected 11 novel and 6 previously described pathogenic mutations in a cohort of 43 patients originating from the Middle East with the acute form HT1. All of the mutations were homozygous and we did not find the presence of a "founder mutation".
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764616     DOI: 10.1016/j.ymgme.2011.06.019

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  8 in total

1.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

2.  The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome.

Authors:  M A Yilmaz; C Duran; M Basaran
Journal:  J Endocrinol Invest       Date:  2015-06-23       Impact factor: 4.256

3.  Clinical experience with hepatorenal tyrosinemia from a single Egyptian center.

Authors:  Hanaa El-Karaksy; Hala Mohsen Abdullatif; Carolyne Morcos Ghobrial; Engy Adel Mogahed; Noha Adel Yasin; Noha Talal; Mohamed Rashed
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.752

4.  Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.

Authors:  Sarar Mohamed; Mohammed A Kambal; Nasir A Al Jurayyan; Abdulrahman Al-Nemri; Amir Babiker; Rana Hasanato; Abdullah S Al-Jarallah
Journal:  BMC Res Notes       Date:  2013-09-09

5.  Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma.

Authors:  Patrick R Blackburn; Raymond D Hickey; Rebecca A Nace; Nasra H Giama; Daniel L Kraft; Andrew J Bordner; Roongruedee Chaiteerakij; Jennifer B McCormick; Maja Radulovic; Rondell P Graham; Michael S Torbenson; Silvia Tortorelli; C Ronald Scott; Noralane M Lindor; Dawn S Milliner; Devin Oglesbee; Wafa'a Al-Qabandi; Markus Grompe; Dimitar K Gavrilov; Mounif El-Youssef; Karl J Clark; Paldeep S Atwal; Lewis R Roberts; Eric W Klee; Stephen C Ekker
Journal:  Hum Mutat       Date:  2016-08-08       Impact factor: 4.878

6.  Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.

Authors:  María Luz Couce; Paula Sánchez-Pintos; Luís Aldámiz-Echevarría; Isidro Vitoria; Victor Navas; Elena Martín-Hernández; Camila García-Volpe; Guillem Pintos; Luis Peña-Quintana; Tomás Hernández; David Gil; Félix Sánchez-Valverde; María Bueno; Iria Roca; Encarna López-Ruzafa; Carmen Díaz-Fernández
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

7.  Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant.

Authors:  Isabel Ibarra-González; Cynthia Fernández-Lainez; Miguel Angel Alcántara-Ortigoza; Ariadna González-Del Angel; Liliana Fernández-Henández; Sara Guillén-López; Leticia Belmont-Martínez; Lizbeth López-Mejía; Gustavo Varela-Fascinetto; Marcela Vela-Amieva
Journal:  Mol Genet Genomic Med       Date:  2019-09-30       Impact factor: 2.183

8.  A case report of two siblings with hypertyrosinemia type 1 presenting with hepatic disease with different onset time and severity.

Authors:  Kazuo Kawabata; Jun Kido; Takanobu Yoshida; Shirou Matsumoto; Kimitoshi Nakamura
Journal:  Mol Genet Metab Rep       Date:  2022-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.